News

2016 Jan 13

Getting a GRASP on the R01 Funding Process

The new Grant Review and Support Program (GRASP) at Weill Cornell Medicine is training assistant professor and instructor level investigators to successfully submit their first National Institutes of Health (NIH) R01 proposal. Read more

2016 Jan 12

Engineering tumor environments for study

Feature on the research of Cornell University member Claudia Fischbach-Teschl, Ph.D. Read more

2016 Jan 11

Increased funding for medical research is a terrific first step

Dean Laurie Glimcher, M.D., pens a piece about federal funding for medical research. Read more

2016 Jan 11

Batting it out of the park

Ph.D. student Katie Gayvert's "Moneyball" approach to cancer involves a computational model to screen for drugs that are too toxic to tolerate. Read more

Dr. Richard Furman and patient Bob Azopardi

2016 Jan 06

Improving the Odds

Feature about the lymphoma program. Read more

2016 Jan 06

Eli Lilly, Pfizer, J&J, AbbVie join $48M bet on NYC cancer drug startup

Director Lewis Cantley, Ph.D., is heading a new pharmaceutical venture. Read more

2016 Jan 04

30 Under 30

Graduate students Kaitlyn Gayvert and Neel Madhukar were named to prestigious Forbes list Read more

2015 Dec 29

Glembatumumab vedotin as a treatment in Triple Negative Breast Cancer

Linda Vahdat, M.D., discusses the antibody drug conjugate glembatumumab vedotin in the treatment of women with triple negative breast cancer. Read more

2015 Dec 23

CLL Research Highlights From ASH 2015

Richard Furman, M.D., gives a rundown of research and treatment advances for chronic lymphocytic leukemia Read more

2015 Dec 22

Immune checkpoint inhibition an ‘important new frontier’ in lymphoma

John P. Leonard, M.D., discusses immune checkpoint inhibitors at the Lymphoma & Myeloma 2015 conference. Read more

2015 Dec 17

Comparing therapies for Hodgkin's lymphoma in varied populations

Peter Martin, M.D., comments on studies comparing therapies for Hodgkin's lymphoma. Read more

2015 Dec 15

New horizons for interferon therapy in MPNs

Richard Silver, M.D., discusses interferon therapy for the treatment of myeloproliferative neoplasms. Read more

2015 Dec 15

Emerging strategies for treating progressive indolent B-Cell NHL

John P. Leonard, M.D., presented on indolent B-Cell NHL treatment at the recent Chemotherapy Foundation Symposium. Read more

2015 Dec 15

Phase II trial tests efficacy of glembatumumab for triple negative breast cancer

Linda Vahdat, M.D., discusses the METRIC trial of antibody-drug conjugate glembatumumab vedotin. Read more

2015 Dec 14

Posthumous honor for hematology legend Aaron Marcus

Aaron J. Marcus, M.D., was recently recognized at the ASH Annual Meeting with the 2015 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Read more

2015 Dec 14

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Peter Martin, comments on phase III trial findings about ibrutinib therapy for relapsed or refractory mantle cell lymphoma. Read more

2015 Dec 14

Lung inflammation contributes to metastasis

Pre-existing inflammation in the lungs may increase the risk that cancers beginning elsewhere will spread to the organ, according to Vivek Mittal, Ph.D., and colleagues. Read more

2015 Dec 14

Amid cancer breakthroughs, hospitals aim for top talent, clinical trials

Dean Laurie Glimcher, M.D., discusses recent big-name cancer recruits at Weill Cornell Medicine. Read more

2015 Dec 11

Surgery in the Aging Patient

Heather Yeo, M.D., MPH, discusses care management for geriatric patients and their caregivers. Read more

2015 Dec 10

Leonard lists his lymphoma highlights

Several trade publications turned to John Leonard, M.D., for his insights into the highlights of the ASH Annual Meeting Read more

News

Getting a GRASP on the R01 Funding Process

Engineering tumor environments for study

Increased funding for medical research is a terrific first step

Batting it out of the park

Improving the Odds

Eli Lilly, Pfizer, J&J, AbbVie join $48M bet on NYC cancer drug startup

30 Under 30

Glembatumumab vedotin as a treatment in Triple Negative Breast Cancer

CLL Research Highlights From ASH 2015

Immune checkpoint inhibition an ‘important new frontier’ in lymphoma

Comparing therapies for Hodgkin's lymphoma in varied populations

New horizons for interferon therapy in MPNs

Emerging strategies for treating progressive indolent B-Cell NHL

Phase II trial tests efficacy of glembatumumab for triple negative breast cancer

Posthumous honor for hematology legend Aaron Marcus

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Lung inflammation contributes to metastasis

Amid cancer breakthroughs, hospitals aim for top talent, clinical trials

Surgery in the Aging Patient

Leonard lists his lymphoma highlights

Follow us on X

2022 Annual Report

2021 Annual Report

2018 Annual Report

2017 Annual Report

2016 Annual Report

Newsletters